This review aims to comprehensively explore the role of S100A8/A9 in ASCVD and ischemic heart disease, HF, and cardiac arrhythmogenesis, and to discuss its pathophysiological implications, clinical significance, and potential utility as a therapeutic target to improve cardiovascular outcomes. This evidence concerns the gene S100A8 and atherosclerosis.